Sometimes a funding increase can be no increase at all.
Addressing the Molecular and Genetics Screening Panel, David Ransohoff, coauthor of the NEJM paper, focused on the future role of noninvasive tests like Cologuard in programs of screening for colorectal cancer.
The Panel's Comments“I typically refrain from commentary, but I will say this: I think this is a phenomenal study, in particular, for one reason,” said FDA panel member Ronald Przygodzki, acting director of Biomedical Laboratory Research and Development at the Department of Veterans Affairs Office of Research & Development.
The FDA Molecular and Clinical Genetics Panel voted 10-0 to recommend approval of Cologuard—a noninvasive, multitarget stool DNA screening test for colorectal cancer.
MD ANDERSON CANCER CENTER signed a three-year translational and clinical research agreement with MedImmune to develop anti-cancer immunotherapies through the center's Moon Shots Program. MedImmune is the global biologics research and development arm of AstraZeneca.
SARAH THAYER was named the Merle M. Musselman Centennial Professor of Surgery and chief of surgical oncology at the University of Nebraska Medical Center. She was also named associate director for clinical affairs and physician-in-chief for the Fred & Pamela Buffett Cancer Center at UNMC.
VENTANA MEDICAL SYSTEMS INC. has entered into a multi-year agreement with Bayer Pharma AG to develop companion diagnostics with a focus on immunohistochemistry, across Bayer's portfolio of targeted therapy projects.
NCI announced the winners of the 2013 Cancer Center Clinical Investigator Team Leadership Awards.
DEBASHISH TRIPATHY joined MD Anderson Cancer Center as breast medical oncology chair.
CHAD ELLIS was named associate director of the University of North Carolina Lineberger Comprehensive Cancer Center, effective April 1.
